Back to top

Arcus Biosciences price target raised to $42 from $34 at Goldman Sachs

Goldman Sachs analyst Richard Law raised the firm’s price target on Arcus Biosciences (RCUS) to $42 from $34 and keeps a Buy rating on the shares. ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Arcus Biosciences, Inc. (RCUS)